BIOMAT Database Logo BIOMAT Database Logo

The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. 1990

D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York.

We studied the metabolic anatomy of typical Parkinson's disease (PD) using [18F]fluorodeoxyglucose (FDG) and [18F]fluorodopa (FDOPA) and positron emission tomography (PET). Fourteen PD patients (mean age 49 years) had FDG/PET scans, of which 11 were scanned with both FDOPA and FDG. After the injection of FDOPA, brain uptake and arterial plasma radioactivity were monitored for 2 h. Striatal FDOPA uptake was analyzed with regard to a two-compartment model, and target-to-background ratios (TBRs) and TBR-versus-time slopes were also calculated. Regional patterns of metabolic covariation were extracted from FDG/PET data using the Scaled Subprofile Model (SSM). SSM pattern weights, FDOPA uptake constants (Ki), TBRs, and TBR slopes were correlated with clinical measures for bradykinesia, rigidity, tremor, gait disturbance, left-right asymmetry, dementia, and overall disease severity. In PD patients, rate constants for FDOPA uptake correlated with individual measures of bradykinesia (p = 0.001) and gait disability (p less than 0.05). SSM analysis revealed a distinct pattern of regional metabolic asymmetries, which correlated with motor asymmetries (p less than 0.001) and left-right differences in Ki (p less than 0.01). Our data suggest that in PD patients, FDG/PET and FDOPA/PET may provide unique and complementary information about underlying disease processes.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D003837 Deoxy Sugars Sugars that in which one or more hydroxyl groups of the pyranose or furanose ring is substituted by hydrogen. Deoxy Sugar,Sugar, Deoxy,Sugars, Deoxy
D003847 Deoxyglucose 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity. 2-Deoxy-D-glucose,2-Deoxyglucose,2-Desoxy-D-glucose,2 Deoxy D glucose,2 Deoxyglucose,2 Desoxy D glucose
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
[18F-fluorodeoxyglucose positron emission tomography in Parkinson's disease].
January 1997, Nihon rinsho. Japanese journal of clinical medicine,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Parkinson's disease: positron emission tomographic studies.
December 1989, Seminars in neurology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.
September 1993, Annals of neurology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
December 1995, Archives of neurology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study.
February 2004, Archives of general psychiatry,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
April 2000, Archives of neurology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.
November 1994, Annals of neurology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
Effect of metformin on 18F-fluorodeoxyglucose uptake and positron emission tomographic imaging.
February 2022, The British journal of radiology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
18F-fluorodeoxyglucose positron emission tomography in Whipple's disease.
December 2006, Scandinavian journal of gastroenterology,
D Eidelberg, and J R Moeller, and V Dhawan, and J J Sidtis, and J Z Ginos, and S C Strother, and J Cedarbaum, and P Greene, and S Fahn, and D A Rottenberg
18F-fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery.
August 2009, Proceedings of the American Thoracic Society,
Copied contents to your clipboard!